Company: IMCR
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001671927-25-000009
Chunk: 18

Company: Immunocore Holdings plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 5,793,501$1 $1,190,104 $(795,761)$(33,763)$360,716 Net income—— —— — 5,023 — 5,023 Other comprehensive income—— —— — — 673 673 Exercise of share options119,749— —— 2,551 — — 2,551 Share-based compensation expense—— —— 9,516 — — 9,516 As of March 31, 202550,184,609$135 5,793,501$1 $1,202,171 $(790,738)$(33,090)$378,479 

Ordinary SharesDeferred SharesAdditional Paid-in  CapitalAccumulateddeficitAccumulated other comprehensive  (loss) incomeTotal Shareholders' EquitySharesAmountSharesAmountAs of December 31, 202349,725,649$134 5,793,501$1 $1,149,643 $(744,674)$(36,261)$368,843 Net loss— — — — — (24,436)— (24,436)Other comprehensive income— — — — — — 897 897 Exercise of share options280,436 1 — — 5,212 — — 5,213 Share-based compensation expense— — — — 9,017 — — 9,017 As of March 31, 202450,006,085$135 5,793,501$1 $1,163,872 $(769,110)$(35,364)$359,534 

The accompanying notes form an integral part of these condensed consolidated financial statements.

4

Immunocore Holdings plc

Condensed Consolidated Statements of Cash Flows

(Unaudited) (In thousands)

Three Months Ended March 31,20252024Cash flows from operating activities Net income (loss)$5,023 $(24,436)Adjustments for:Share-based compensation expense9,489 8,964 Depreciation854 1,011 Unrealized foreign exchange (gains) losses, net(2,907)1,304 Unrealized gains on marketable securities(5,469)— Non-cash lease expense546 432 Other509 (